A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Background: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon‐like‐peptide‐1 (GLP‐1) receptor agonist could be a treatment option for adolescent obesity. Objective: To investigate the effect of exenatide extended release on body mass index (BMI)‐SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity. Methods: Six‐month, randomized, double‐blinded, parallel, placebo‐controlled clinical trial in patients (n = 44, 10‐18 years, females n = 22) with BMI‐SDS > 2.0 or age‐adapted‐BMI > 30 kg/m 2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention. Results: Exenatide reduced (P < .05) BMI‐SDS (−0.09; −0.18, 0.00), % BMI 95th percentile (−2.9%; −5.4, −0.3), weight (−3 kg; −5.8, −0.1), waist circumference (−3.2 cm; −5.8, −0.7), subcutaneous adipose tissue (−552 cm 3; −989, −114), 2‐hour‐glucose during OGTT (−15.3 mg/dL; −27.5, −3.1), total cholesterol (11.6 mg/dL; −21.7, −1.5), and BMI (−0.83 kg/m 2; −1.68, 0.01) without significant change in liver fat content (−1.36; −3.12, 0.4; P = .06) in comparison to placebo. Safety and tolerability profiles were comparable to placebo with the exception of mild adverse events being more frequent in exenatide‐treated patients. Conclusions: Treatment of adolescents with severe obesity with extended‐release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · cited 4×
“9,10 The reducing effect of the GLP-1 analogue may be of considerable importance given the increased risk of adolescents with obesity to develop cardiovascular disease, glucose intolerance, and T2DM.”
BackgroundInfluentialFlegal, K. M., Wei, R., Ogden, C. L., Freedman, D. S., Johnson, C. L., & Curtin, L. R. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28335 · Cited by 435
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Bizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Cited by
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730
Self-citationA Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1844-1176 · Cited by 59
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Metadata
- Authors
- Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., Hofmann, J., Kristinsson, H., Kullberg, J., Ladinger, A., Lagler, F. B., Lidström, M., Manell, H., Meirik, M., Mörwald, K., Roomp, K., Schneider, R., Vilén, H., Widhalm, K., Zsoldos, F., & Bergsten, P.
- Venue
- Pediatric Obesity
- Publisher
- Wiley
- Published
- 2020-02-16
- Volume
- 15
- Issue
- 7
- Pages
- e12624-e12624
- ISSN
- 2047-6302 (ISSN-L)
- 2047-6310
- OpenAlex
- W3005805429
- Cited by
- 78
- References
- 7
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity. https://app.cochat.ai/papers/10.1111/ijpo.12624
- The paper
- Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., Hofmann, J., Kristinsson, H., Kullberg, J., Ladinger, A., Lagler, F. B., Lidström, M., Manell, H., Meirik, M., Mörwald, K., . . . Bergsten, P. (2020). A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity. Pediatric Obesity. https://doi.org/10.1111/ijpo.12624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.